{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:04:01Z","timestamp":1790013841372,"version":"4.0.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04181-6","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:41:14Z","timestamp":1786477274000},"page":"2589-2606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vitro\u2013In Vivo Correlation (IVIVC) in Transdermal Drug Delivery Systems: Models, Regulatory Perspectives and Translational Challenges"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3166-2624","authenticated-orcid":false,"given":"Uday Sankar","family":"Chakrabarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0131-8549","authenticated-orcid":false,"given":"Amrita","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1986-3304","authenticated-orcid":false,"given":"Mainak","family":"Mal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5781-3106","authenticated-orcid":false,"given":"Dibya","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"11","key":"4181_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261\u20138.","journal-title":"Nat Biotechnol"},{"key":"4181_CR2","unstructured":"Barry BW. Dermatological formulations. Percutaneous absorption. In: Swarbrick J, editor. Drugs and the pharmaceutical sciences, vol. 18. New York: Marcel Dekker; 1983."},{"issue":"12","key":"4181_CR3","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/j.bbamem.2006.06.021","volume":"1758","author":"JA Bouwstra","year":"2006","unstructured":"Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochim Biophys Acta. 2006;1758(12):2080\u201395.","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20132","key":"4181_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(01)00731-1","volume":"224","author":"J Hadgraft","year":"2001","unstructured":"Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1\u20132):1\u201318.","journal-title":"Int J Pharm"},{"issue":"1","key":"4181_CR5","first-page":"1","volume":"29","author":"JE Riviere","year":"2006","unstructured":"Riviere JE. Comparative pharmacokinetics of dermal absorption. J Vet Pharmacol Ther. 2006;29(1):1\u20139.","journal-title":"J Vet Pharmacol Ther"},{"issue":"2\u20133","key":"4181_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0169-409X(01)00113-2","volume":"48","author":"YN Kalia","year":"2001","unstructured":"Kalia YN, Guy RH. Modeling transdermal drug release. Adv Drug Deliv Rev. 2001;48(2\u20133):159\u201372.","journal-title":"Adv Drug Deliv Rev"},{"key":"4181_CR7","volume-title":"Transdermal and topical delivery systems\u2014product development and quality considerations: guidance for industry","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. Transdermal and topical delivery systems\u2014product development and quality considerations: guidance for industry. Silver Spring (MD): U.S. Food and Drug Administration; 2019."},{"issue":"3","key":"4181_CR8","first-page":"307","volume":"116","author":"A Rougier","year":"1987","unstructured":"Rougier A, et al. Regional variation in percutaneous absorption. Br J Dermatol. 1987;116(3):307\u201316.","journal-title":"Br J Dermatol"},{"issue":"2","key":"4181_CR9","first-page":"169","volume":"9","author":"J Emami","year":"2006","unstructured":"Emami J. In vitro\u2013in vivo correlation: from theory to applications. J Pharm Pharm Sci. 2006;9(2):169\u201389.","journal-title":"J Pharm Pharm Sci"},{"key":"4181_CR10","volume-title":"Extended release oral dosage forms: development, evaluation, and application of in vitro\/in vivo correlations: guidance for industry","author":"U.S. Food and Drug Administration","year":"1997","unstructured":"U.S. Food and Drug Administration. Extended release oral dosage forms: development, evaluation, and application of in vitro\/in vivo correlations: guidance for industry. Rockville (MD): U.S. Food and Drug Administration; 1997."},{"issue":"3","key":"4181_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1208\/s12248-012-9359-0","volume":"14","author":"JM Cardot","year":"2012","unstructured":"Cardot JM, Davit B. In vitro\u2013in vivo correlations: tricks and traps. AAPS J. 2012;14(3):491\u20139.","journal-title":"AAPS J"},{"issue":"Suppl","key":"4181_CR12","doi-asserted-by":"publisher","first-page":"44s","DOI":"10.1038\/jid.1983.12","volume":"80","author":"PM Elias","year":"1983","unstructured":"Elias PM. Epidermal lipids, barrier function and desquamation. J Invest Dermatol. 1983;80(Suppl):44s\u20139s.","journal-title":"J Invest Dermatol"},{"key":"4181_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2012.09.032","volume":"64","author":"AC Williams","year":"2012","unstructured":"Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128\u201337.","journal-title":"Adv Drug Deliv Rev"},{"key":"4181_CR14","first-page":"93","volume-title":"Principles of route-to-route extrapolation for risk assessment","author":"GL Flynn","year":"1990","unstructured":"Flynn GL. Physicochemical determinants of skin absorption. In: Gerrity TR, Henry CJ, editors. Principles of route-to-route extrapolation for risk assessment. New York: Elsevier; 1990. p. 93\u2013127."},{"key":"4181_CR15","volume-title":"Dermal absorption and toxicity assessment","author":"MS Roberts","year":"2002","unstructured":"Roberts MS, Cross SE, Pellett MA. Skin transport. In: Roberts MS, Walters KA, editors. Dermal absorption and toxicity assessment. New York: Marcel Dekker; 2002."},{"issue":"5","key":"4181_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/BF01059549","volume":"8","author":"S Riegelman","year":"1980","unstructured":"Riegelman S, Collier P. The application of statistical moment theory to pharmacokinetics. J Pharmacokinet Biopharm. 1980;8(5):509\u201334.","journal-title":"J Pharmacokinet Biopharm"},{"key":"4181_CR17","first-page":"85","volume":"11","author":"T Higuchi","year":"1960","unstructured":"Higuchi T. Physical chemical analysis of percutaneous absorption process. J Soc Cosmet Chem. 1960;11:85\u201397.","journal-title":"J Soc Cosmet Chem"},{"issue":"1","key":"4181_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0168-3659(87)90066-6","volume":"6","author":"BW Barry","year":"1987","unstructured":"Barry BW. Mode of action of penetration enhancers in human skin. J Control Release. 1987;6(1):85\u201397.","journal-title":"J Control Release"},{"issue":"7","key":"4181_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1023\/A:1016298012408","volume":"12","author":"AL Bunge","year":"1995","unstructured":"Bunge AL, Cleek RL. A new method for estimating dermal absorption from chemical exposure. Pharm Res. 1995;12(7):972\u201382.","journal-title":"Pharm Res"},{"issue":"2\u20133","key":"4181_CR20","first-page":"185","volume":"48","author":"MS Roberts","year":"2001","unstructured":"Roberts MS, Anissimov YG. Modeling of percutaneous absorption. Adv Drug Deliv Rev. 2001;48(2\u20133):185\u2013209.","journal-title":"Adv Drug Deliv Rev"},{"key":"4181_CR21","doi-asserted-by":"crossref","unstructured":"Hadgraft J, Guy RH. Feasibility assessment in topical and transdermal delivery: mathematical models and in vitro studies. In: Guy RH, Hadgraft J, editors. Transdermal drug delivery. 2nd ed.,\u00a0revised and expanded. New York: Marcel Dekker; 2003. p. 1\u201323.","DOI":"10.1201\/9780203909683-1"},{"issue":"3","key":"4181_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000131079","volume":"21","author":"J Lademann","year":"2008","unstructured":"Lademann J, et al. Hair follicles as pathways for topically applied substances. Skin Pharmacol Physiol. 2008;21(3):150\u20135.","journal-title":"Skin Pharmacol Physiol"},{"key":"4181_CR23","doi-asserted-by":"crossref","unstructured":"Guy RH, Hadgraft J, editors. Transdermal drug delivery. 2nd ed., revised and expanded. New York: Marcel Dekker; 2003.","DOI":"10.1201\/9780203909683"},{"key":"4181_CR24","volume-title":"Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms. London: European Medicines Agency; 2014."},{"key":"4181_CR25","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. SUPAC-MR: modified release solid oral\u00a0dosage forms scale-up and post approval changes: chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation: guidance for industry. Rockville (MD): U.S. Food and Drug Administration; 1997."},{"issue":"Suppl 2","key":"4181_CR26","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/S0928-0987(00)00181-0","volume":"11","author":"JB Dressman","year":"2000","unstructured":"Dressman JB, Reppas C. In vitro\u2013in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000;11(Suppl 2):S73\u201380.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4181_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1011941929495","volume":"15","author":"VP Shah","year":"1998","unstructured":"Shah VP, et al. Bioequivalence of topical dermatological dosage forms\u2014methods and challenges. Pharm Res. 1998;15(2):167\u201371.","journal-title":"Pharm Res"},{"issue":"1","key":"4181_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12248-008-9010-2","volume":"10","author":"RA Lionberger","year":"2008","unstructured":"Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10(1):103\u20139.","journal-title":"AAPS J"},{"issue":"3\u20134","key":"4181_CR29","first-page":"333","volume":"50","author":"JM Cardot","year":"2013","unstructured":"Cardot JM, Beyssac E. In vitro\u2013in vivo correlation: importance of dissolution in IVIVC. Eur J Pharm Sci. 2013;50(3\u20134):333\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"4181_CR30","first-page":"111","volume":"18","author":"VP Shah","year":"2001","unstructured":"Shah VP. IVIVC: regulatory and scientific considerations. Pharm Res. 2001;18:111\u20134.","journal-title":"Pharm Res"},{"key":"4181_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijpharm.2005.07.014","volume":"305","author":"J Hadgraft","year":"2005","unstructured":"Hadgraft J, Lane ME. Skin permeation: variability and modelling. Int J Pharm. 2005;305:2\u201312.","journal-title":"Int J Pharm"},{"key":"4181_CR32","first-page":"529","volume":"62","author":"K Sugibayashi","year":"2010","unstructured":"Sugibayashi K, et al. Skin permeation and modelling. Adv Drug Deliv Rev. 2010;62:529\u201341.","journal-title":"Adv Drug Deliv Rev"},{"key":"4181_CR33","first-page":"121","volume":"57","author":"S Mitragotri","year":"2011","unstructured":"Mitragotri S, et al. Mathematical models of skin permeability. AIChE J. 2011;57:121\u201332.","journal-title":"AIChE J"},{"key":"4181_CR34","volume-title":"Physiologically based pharmacokinetic modelling: methods and applications in the pharmaceutical industry","author":"SA Peters","year":"2012","unstructured":"Peters SA. Physiologically based pharmacokinetic modelling: methods and applications in the pharmaceutical industry. Hoboken (NJ): John Wiley & Sons; 2012."},{"key":"4181_CR35","volume-title":"Guidance document for the conduct of skin absorption studies","author":"Organisation for Economic Co-operation and Development","year":"2004","unstructured":"Organisation for Economic Co-operation and Development. Guidance document for the conduct of skin absorption studies. Paris: OECD; 2004. OECD Environment, Health and Safety Publications, Series on Testing and Assessment No. 28; ENV\/JM\/MONO (2004) 2."},{"key":"4181_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/1523-1747.ep12533356","volume":"64","author":"TJ Franz","year":"1975","unstructured":"Franz TJ. Percutaneous absorption methodology. J Invest Dermatol. 1975;64:190\u20135.","journal-title":"J Invest Dermatol"},{"key":"4181_CR37","unstructured":"OECD. Test Guideline 428: skin absorption: in vitro method. 2004."},{"key":"4181_CR38","unstructured":"Bronaugh RL, Maibach HI, editors. Percutaneous absorption: mechanisms\u2014methodology\u2014drug delivery. 2nd ed.,  revised and expanded. New York: Marcel Dekker; 1989."},{"key":"4181_CR39","unstructured":"Organisation for Economic Co-operation and Development. Guidance notes on dermal absorption. Paris: OECD; 2011. OECD Series on Testing and Assessment No. 156; ENV\/JM\/MONO (2011) 36."},{"key":"4181_CR40","first-page":"551","volume":"6","author":"IP Dick","year":"1992","unstructured":"Dick IP, Scott RC. Human skin permeability studies. Toxicol In Vitro. 1992;6:551\u20137.","journal-title":"Toxicol In Vitro"},{"key":"4181_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000029928","volume":"13","author":"GA Simon","year":"2000","unstructured":"Simon GA, Maibach HI. Porcine skin model. Skin Pharmacol Physiol. 2000;13:229\u201334.","journal-title":"Skin Pharmacol Physiol"},{"key":"4181_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0846.2006.00179.x","volume":"13","author":"U Jacobi","year":"2007","unstructured":"Jacobi U, et al. Porcine vs human skin permeation. Skin Res Technol. 2007;13:19\u201324.","journal-title":"Skin Res Technol"},{"key":"4181_CR43","first-page":"1","volume":"385","author":"SF Ng","year":"2010","unstructured":"Ng SF, et al. Synthetic membranes in skin permeation. Int J Pharm. 2010;385:1\u201311.","journal-title":"Int J Pharm"},{"issue":"3","key":"4181_CR44","first-page":"405","volume":"1","author":"AL Bunge","year":"2005","unstructured":"Bunge AL, Mitragotri S. Mechanistic modelling of transdermal drug delivery: opportunities for future research. Expert Opin Drug Metab Toxicol. 2005;1(3):405\u201316.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4181_CR45","volume":"187","author":"K Sugibayashi","year":"2022","unstructured":"Sugibayashi K, Morimoto Y. Development of predictive in vitro and in silico tools for transdermal drug delivery. Adv Drug Deliv Rev. 2022;187: 114373.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"4181_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.02.040","volume":"447","author":"ME Lane","year":"2013","unstructured":"Lane ME. Skin penetration enhancers and IVIVC: research gaps and opportunities. Int J Pharm. 2013;447(1\u20132):12\u201321.","journal-title":"Int J Pharm"},{"key":"4181_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000401276","volume":"7","author":"TJ Franz","year":"1978","unstructured":"Franz TJ. The finite dose technique as a valid in vitro model for the study of percutaneous absorption. Curr Probl Dermatol. 1978;7:58\u201368.","journal-title":"Curr Probl Dermatol"},{"issue":"1\u20133","key":"4181_CR48","first-page":"1","volume":"50","author":"KR Brain","year":"1998","unstructured":"Brain KR, Walters KA. Franz diffusion cells in transdermal research. J Control Release. 1998;50(1\u20133):1\u201312.","journal-title":"J Control Release"},{"issue":"3","key":"4181_CR49","first-page":"352","volume":"83","author":"D Selzer","year":"2013","unstructured":"Selzer D, Abdel-Mottaleb MMA, Hahn T, Schaefer UF, Neumann D. Finite and infinite dosing in skin permeation experiments. Eur J Pharm Biopharm. 2013;83(3):352\u201360.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"4181_CR50","first-page":"200","volume":"42","author":"RP Chilcott","year":"2005","unstructured":"Chilcott RP, Jenner J, Carrick W. Flow-through diffusion cells in dermal absorption studies. Regul Toxicol Pharmacol. 2005;42(2):200\u20138.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"4181_CR51","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ejps.2013.02.020","volume":"50","author":"D Karadzovska","year":"2013","unstructured":"Karadzovska D, Riviere JE. Flow-through systems in dermal delivery studies. Eur J Pharm Sci. 2013;50(5):569\u201388.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4181_CR52","first-page":"1","volume":"102","author":"JM Nitsche","year":"2013","unstructured":"Nitsche JM, Kasting GB. Mechanistic modelling of dermal drug delivery. J Pharm Sci. 2013;102(2):1\u201314.","journal-title":"J Pharm Sci"},{"issue":"2","key":"4181_CR53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejpb.2005.03.004","volume":"60","author":"F Netzlaff","year":"2005","unstructured":"Netzlaff F, Kostka KH, Lehr CM, Schaefer UF. Experimental variables in skin permeation studies. Eur J Pharm Biopharm. 2005;60(2):295\u2013303.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"4181_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1567201052772915","volume":"2","author":"HAE Benson","year":"2005","unstructured":"Benson HAE. Transdermal drug delivery variables. Curr Drug Deliv. 2005;2(1):23\u201333.","journal-title":"Curr Drug Deliv"},{"key":"4181_CR55","unstructured":"Barry BW. Dermatological formulations and transdermal systems. Marcel Dekker. 2002."},{"issue":"Suppl 1","key":"4181_CR56","first-page":"S23","volume":"54","author":"MS Roberts","year":"2002","unstructured":"Roberts MS, Cross SE, Pellett MA. Skin transport variability. Adv Drug Deliv Rev. 2002;54(Suppl 1):S23\u201330.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"4181_CR57","first-page":"1","volume":"21","author":"RA Lionberger","year":"2019","unstructured":"Lionberger RA. Model-informed drug development. AAPS J. 2019;21(3):1\u20139 (74).","journal-title":"AAPS J."},{"issue":"7","key":"4181_CR58","first-page":"514","volume":"10","author":"M Rowland","year":"2011","unstructured":"Rowland M, Peck C, Tucker G. Physiologically based pharmacokinetics. Nat Rev Drug Discov. 2011;10(7):514\u201326.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4181_CR59","first-page":"67","volume":"47","author":"SA Peters","year":"2008","unstructured":"Peters SA. Evaluation of PBPK modeling. Clin Pharmacokinet. 2008;47(2):67\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"4181_CR60","first-page":"1043","volume":"21","author":"GB Kasting","year":"2007","unstructured":"Kasting GB, Miller MA, Kasting NS, Jalil B. Human skin permeation studies: interpretation and variability. Toxicol In Vitro. 2007;21:1043\u201354.","journal-title":"Toxicol In Vitro"},{"issue":"6","key":"4181_CR61","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s12272-013-0035-4","volume":"36","author":"Y-I Kim","year":"2013","unstructured":"Kim Y-I, Jeong YI, Choi MJ, Park JB, Kim DD. In vitro\u2013in vivo correlation (IVIVC) for transdermal drug delivery systems: a review. Arch Pharm Res. 2013;36(6):745\u201354.","journal-title":"Arch Pharm Res"},{"key":"4181_CR62","first-page":"46","volume":"141","author":"A Casiraghi","year":"2019","unstructured":"Casiraghi A, Spada F, Colombo P. Predictive in vitro\u2013in vivo correlations for transdermal therapeutic systems: mechanistic approaches and regulatory perspectives. Eur J Pharm Biopharm. 2019;141:46.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"4181_CR63","first-page":"49","volume":"5","author":"M Patel","year":"2010","unstructured":"Patel M, Gohel MC, Soniwala MM, Soni ST. In vitro\u2013in vivo correlation and its role in transdermal drug delivery systems. Int J Pharm Sci Rev Res. 2010;5(3):49\u201355.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"7","key":"4181_CR64","first-page":"2501","volume":"110","author":"TK Ghosh","year":"2021","unstructured":"Ghosh TK, Bagchi P. Machine learning in transdermal drug delivery: predictive modelling of skin permeability and IVIVC. J Pharm Sci. 2021;110(7):2501\u201316.","journal-title":"J Pharm Sci"},{"issue":"19","key":"4181_CR65","first-page":"3178","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Li X, Wang Y, Lin H, Wang F. Microfluidic skin-on-a-chip systems for transdermal drug testing. Lab Chip. 2017;17(19):3178\u201394.","journal-title":"Lab Chip"},{"issue":"6","key":"4181_CR66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000511443","volume":"33","author":"S Nolte","year":"2020","unstructured":"Nolte S, Lademann J, Meinke MC. Advanced in vitro skin models for mechanistic IVIVC in transdermal drug delivery. Skin Pharmacol Physiol. 2020;33(6):293\u2013307.","journal-title":"Skin Pharmacol Physiol"},{"issue":"6","key":"4181_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.addr.2011.01.012","volume":"63","author":"TW Prow","year":"2011","unstructured":"Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470\u201391.","journal-title":"Adv Drug Deliv Rev"},{"key":"4181_CR68","unstructured":"Zhai H, Maibach HI. Influence of skin site, gender and age on percutaneous absorption. In: Guy RH, Hadgraft J, editors. Transdermal drug delivery. New York: Marcel Dekker; 2003. p. 33\u201354."},{"issue":"1\u20132","key":"4181_CR69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.02.040","volume":"447","author":"ME Lane","year":"2013","unstructured":"Lane ME. Skin penetration enhancers. Int J Pharm. 2013;447(1\u20132):12\u201321.","journal-title":"Int J Pharm"},{"issue":"10","key":"4181_CR70","first-page":"2514","volume":"107","author":"N Padoin","year":"2018","unstructured":"Padoin N, Hein D, Silva L, de Souza T, Guterres S. Case examples of in vitro\u2013in vivo correlation for transdermal systems: lessons learned and practical insights. J Pharm Sci. 2018;107(10):2514\u201326.","journal-title":"J Pharm Sci"},{"issue":"3","key":"4181_CR71","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/10717540500455975","volume":"13","author":"MB Brown","year":"2006","unstructured":"Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175\u201387.","journal-title":"Drug Deliv"},{"key":"4181_CR72","first-page":"56","volume":"139","author":"T Rades","year":"2019","unstructured":"Rades T, et al. Challenges in transdermal drug delivery: formulation, variability and regulatory perspectives. Eur J Pharm Biopharm. 2019;139:56\u201368.","journal-title":"Eur J Pharm Biopharm"},{"key":"4181_CR73","first-page":"120","volume":"20","author":"GB Kasting","year":"2007","unstructured":"Kasting GB, Miller MA. Physiologically based modeling of dermal drug delivery: a critical review. Skin Pharmacol Physiol. 2007;20:120\u201330.","journal-title":"Skin Pharmacol Physiol"},{"issue":"12","key":"4181_CR74","first-page":"1093","volume":"26","author":"GA Simon","year":"2000","unstructured":"Simon GA, Maibach HI. The variability of percutaneous absorption. Dermatol Surg. 2000;26(12):1093\u20139.","journal-title":"Dermatol Surg"},{"issue":"7","key":"4181_CR75","first-page":"427","volume":"51","author":"SA Peters","year":"2012","unstructured":"Peters SA, et al. Physiologically based pharmacokinetic modeling in dermal drug delivery: opportunities and challenges. Clin Pharmacokinet. 2012;51(7):427\u201340.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"4181_CR76","first-page":"1792","volume":"30","author":"VP Shah","year":"2013","unstructured":"Shah VP, et al. Application of PBPK modelling for in vitro\u2013in vivo correlation in transdermal systems. Pharm Res. 2013;30(7):1792\u2013802.","journal-title":"Pharm Res"},{"key":"4181_CR77","unstructured":"Food and Drug Administration. Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs: draft guidance for industry. Silver Spring, MD: US FDA; 12. Food and Drug Administration."},{"key":"4181_CR78","volume-title":"M9 Biopharmaceutics Classification System-Based Biowaivers: Guidance for Industry","author":"Food and Drug Administration","year":"2021","unstructured":"Food and Drug Administration. M9 Biopharmaceutics Classification System-Based Biowaivers: Guidance for Industry. Silver Spring (MD): U.S. Food and Drug Administration; 2021."},{"key":"4181_CR79","volume-title":"WHO guideline on biopharmaceutics classification system-based biowaivers","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO guideline on biopharmaceutics classification system-based biowaivers. Geneva: World Health Organization; 2024. WHO Technical Report Series No. 1052, Annex 7."},{"key":"4181_CR80","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH M9:biopharmaceutics classification system-based biowaivers. Geneva: International Council for Harmonisation; 2019."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04181-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:02:54Z","timestamp":1790010174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04181-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04181-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable to the study.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to the study.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to the study.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to the study.","order":4,"name":"Ethics","label":"Animal Studies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to the study.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author(s) used Gemini to facilitate deep searching. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":6,"name":"Ethics","label":"Declaration of Generative AI and AI-assisted Technologies in the Manuscript Preparation Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}